idiopathic pulmonary fibrosis

Bristol Myers Squibb eyes phase 3 after pulmonary fibrosis drug reduces lung function decline
Bristol Myers Squibb eyes phase 3 after pulmonary fibrosis drug reduces lung function decline
Fierce Biotech
Bristol Myers Squibb
clinical trials
BMS-986278
idiopathic pulmonary fibrosis
Flag link:
Aria Pharmaceuticals Secures Six Provisional Patents for Pipeline Candidates
Aria Pharmaceuticals Secures Six Provisional Patents for Pipeline Candidates
BioSpace
Aria Pharmaceuticals
patents
lupus
idiopathic pulmonary fibrosis
IPH
chronic kidney disease
Flag link:
With new data, Pliant drug shows promise in tough-to-treat lung disease
With new data, Pliant drug shows promise in tough-to-treat lung disease
BioPharma Dive
Pliant Therapeutics
idiopathic pulmonary fibrosis
IPF
PLN-74809
clinical trials
Flag link:
BenevolentAI, AstraZeneca AI-based drug discovery collaboration achieves third milestone
BenevolentAI, AstraZeneca AI-based drug discovery collaboration achieves third milestone
Pharmaforum
BenevolentAI
idiopathic pulmonary fibrosis
AstraZeneca
artificial intelligence
drug development
Flag link:
Starna Therapeutics emerges with financing for mRNA vaccine and therapies
Starna Therapeutics emerges with financing for mRNA vaccine and therapies
Endpoints
Starna Therapeutics
funding
RSV
idiopathic pulmonary fibrosis
Flag link:
Novartis' Sandoz strikes at Roche with first US generic of blockbuster Esbriet
Novartis' Sandoz strikes at Roche with first US generic of blockbuster Esbriet
Fierce Pharma
Novartis
Sandoz
generics
Roche
Esbriet
idiopathic pulmonary fibrosis
Flag link:
Boehringer secures FDA’s Breakthrough Therapy Designation for oral therapy
Boehringer secures FDA’s Breakthrough Therapy Designation for oral therapy
Pharmaceutical Business Review
Boehringer Ingelheim
idiopathic pulmonary fibrosis
FDA
BI 1015550
breakthrough status
Flag link:
AbbVie ditches fibrosis program it paid Morphic $20M for in 2020
AbbVie ditches fibrosis program it paid Morphic $20M for in 2020
Fierce Biotech
AbbVie
Morphic Therapeutic
idiopathic pulmonary fibrosis
Flag link:
Endeavor Bio adds $101M to test ex-Eli Lilly, Roche drug in cancer & lung fibrosis
Endeavor Bio adds $101M to test ex-Eli Lilly, Roche drug in cancer & lung fibrosis
MedCity News
Endeavor BioMedicines
taladegib
cancer
Eli Lilly
Roche
idiopathic pulmonary fibrosis
Flag link:
The lung fibrosis pipeline thins
The lung fibrosis pipeline thins
EP Vantage
idiopathic pulmonary fibrosis
IPF
Pliant Therapeutics
PLN-74809
Flag link:
NeRRe nabs £20M to test chronic cough drug in patients with a fatal lung disease
NeRRe nabs £20M to test chronic cough drug in patients with a fatal lung disease
MedCity News
NeRRe
clinical trial
idiopathic pulmonary fibrosis
clinical trials
Flag link:
Galapagos “win” highlights crowded idiopathic pulmonary fibrosis pipeline
Galapagos “win” highlights crowded idiopathic pulmonary fibrosis pipeline
EP Vantage
Galapagos
GLPG1205
idiopathic pulmonary fibrosis
clinical trials
Flag link:
Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward
Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward
Xconomy
Galecto Biotech
idiopathic pulmonary fibrosis
IPF
GB0139
Flag link:
AbbVie options integrin-based compounds from Morphic, paving way for potential fibrosis treatments
AbbVie options integrin-based compounds from Morphic, paving way for potential fibrosis treatments
Endpoints
Morphic Therapeutics
AbbVie
idiopathic pulmonary fibrosis
Flag link:
Roche buys U.S. drugmaker Promedior for up to $1.4 billion to get lung drug
Roche buys U.S. drugmaker Promedior for up to $1.4 billion to get lung drug
Reuters
Roche
Promedior
idiopathic pulmonary fibrosis
M&A
Flag link:
Boehringer Ingelheim's Ofev cuts rate of decline by 57% in range of rare lung diseases
Boehringer Ingelheim's Ofev cuts rate of decline by 57% in range of rare lung diseases
Fierce Pharma
Boehringer Ingelheim
Ofev
idiopathic pulmonary fibrosis
Flag link:
Biogen stops Phase 2 study in another hit to 'high-risk' pipeline
Biogen stops Phase 2 study in another hit to 'high-risk' pipeline
Biopharma Dive
Biogen
clinical trials
IPF
idiopathic pulmonary fibrosis
BG00011
Flag link:
Trevi Therapeutics jumps on the biotech IPO train
Trevi Therapeutics jumps on the biotech IPO train
Fierce Biotech
IPOs
Trevi Therapeutics
idiopathic pulmonary fibrosis
levodopa-induced dyskinesia
chronic pruritus
Flag link:
Genentech Plans Legal Battle to Protect Esbriet from Generic Competition
Genentech Plans Legal Battle to Protect Esbriet from Generic Competition
BioSpace
Genentech
Roche
idiopathic pulmonary fibrosis
Esbriet
generics
Flag link:
Galecto Biotech Books $89 Million in Series C Financing to Develop Fibrosis Candidate
Galecto Biotech Books $89 Million in Series C Financing to Develop Fibrosis Candidate
CP Wire
Galecto Biotech
TD139
idiopathic pulmonary fibrosis
Flag link:

Pages